Another pre-clinical example is that menin inhibitor SNDX-5613 combined with BCL2 inhibitor venetoclax shows synergistic activity in patient-derived KMT2Ar AML cells and PDX mouse models (Fiskus et al., 2022). The gene discussed is BCL2; the disease is acute myeloid leukemia.